UPMC Fatty Liver Disease Program Clinical Trials

At the UPMC Fatty Liver Disease Program, our team closely monitors clinical trials.

The team includes:

  • Doctors
  • Nurses
  • Research assistants
  • Data analysts

If you're thinking about taking part in a clinical trial, it's important to:

  • Discuss your health and review your records with your care team to decide eligibility.
  • Ask your care team to help you discuss your decision with family members and caregivers.
  • Remember that taking part in a research study is voluntary. You may choose — or someone on the clinical trial team may ask you — to cease participation at any time.

Featured Clinical Trails and Research on Fatty Liver Disease

Intercept: REGENERATE Study on the Safety and Efficacy of Obeticholic Acid for Nonalcoholic Steatohepatitis (NASH)

A phase three, double blind, randomized, long-term, placebo-controlled, multicenter study.

Who can participate People with biopsy-proven noncirrhotic NASH.
What we'll study Study randomized investigational oral drug vs. placebo and protocol testing at no cost to participants.
How we'll conduct the study Participants randomized to chance of study drug or placebo for 18 months. Then may continue with active study drug for all participants (no placebo after 18 months).
Length of the study Up to six years.
Status Actively enrolling.
Who to contact Amy Roundtree Schmotzer, RN, at 412-802-8567 or schmotzerar@upmc.edu.

Gilead: A Study on the Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination with Simtuzumab (SIM) for NASH and Fibrosis Stages F2-F3

A phase two, randomized, open label study.

Who can participate People with biopsy-proven noncirrhotic NASH.
What we'll study Study randomized investigational drug vs. placebo and protocol testing at no cost to participants.
How we'll conduct the study Study participants taking medication for 24 weeks, then see them four weeks later for safety evaluation.
Status Closed to accrual. Participants on follow up.
Who to contact Amy Roundtree Schmotzer, RN, at 412-802-8567 or schmotzerar@upmc.edu.

Contact Us About Fatty Liver Disease Clinical Trials

For more information about clinical trials, please contact Amy Roundtree Schmotzer, RN, at 412-802-8567 or schmotzerar@upmc.edu.

To make an appointment for care, contact the UPMC Fatty Liver Disease Program at 412-647-1170.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences | Supplemental content provided by Healthwise, Incorporated. To learn more, visit www.healthwise.org

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

UPMC
Pittsburgh, PA, USA | UPMC.com